Company news

Verrica Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

March 1, 2022

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

December 14, 2021

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

November 28, 2021

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

November 17, 2021

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 11, 2021

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

September 19, 2021

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 9, 2021

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

July 8, 2021

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

May 27, 2021

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

May 11, 2021

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

May 6, 2021

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

April 5, 2021

Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association

March 28, 2021

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

March 16, 2021

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

March 3, 2021

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

March 2, 2021

Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

February 16, 2021

Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum

November 16, 2020

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference

November 11, 2020

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

November 9, 2020

Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results

November 8, 2020

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference

September 8, 2020

Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications

August 10, 2020

Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results

August 4, 2020

Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan

August 4, 2020

Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors

July 22, 2020

Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes

July 22, 2020

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

July 13, 2020

Verrica Pharmaceuticals Provides Regulatory Update on VP-102

June 28, 2020

Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum

June 11, 2020

Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors

June 9, 2020

Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results

May 6, 2020

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results

March 12, 2020

Verrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities

January 28, 2020

Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102

January 17, 2020

Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

November 26, 2019

Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

November 18, 2019

Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 5, 2019

Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

October 17, 2019

Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

October 8, 2019

Verrica Pharmaceuticals Announces Leadership Team Update

October 6, 2019

Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

September 15, 2019

← Newer news releases

Calls

The 5 newest of 11 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.